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We report the emergence of leptospirosis-associated 
severe pulmonary hemorrhagic syndrome (SPHS) in slum 
communities in Salvador, Brazil. Although active surveil-
lance did not identify SPHS before 2003, 47 cases were 
identiﬁ  ed from 2003 through 2005; the case-fatality rate was 
74%. By 2005, SPHS caused 55% of the deaths due to lep-
tospirosis.
L
eptospirosis, a spirochetal zoonotic disease, is increas-
ingly recognized as an important cause of hemorrhagic 
fever (1–4). The classic presentation of severe leptospiro-
sis, Weil’s disease, is characterized by jaundice, acute renal 
failure, and bleeding. However, the 1995 Nicaragua out-
break raised awareness for leptospirosis as the cause of a 
severe pulmonary hemorrhagic syndrome (SPHS) (5). This 
syndrome, ﬁ  rst identiﬁ  ed in South Korea and People’s Re-
public of China (6), is now reported worldwide (2). SPHS 
is associated with fatality rates of >50% and in certain set-
tings, has replaced Weil’s disease as the cause of death 
among leptospirosis patients (7–10).
The factors responsible for SPHS and its emergence 
are not well understood. In Brazil, outbreaks of leptospi-
rosis occur annually in slum communities during seasonal 
periods of heavy rainfall (11). Although SPHS is a fre-
quently observed manifestation of leptospirosis in Rio de 
Janeiro and São Paulo (7,8,12), the occurrence of SPHS 
varies according to geographic region. In the city of Sal-
vador (population 2.7 million), active surveillance did not 
detect SPHS among 1,786 leptospirosis cases identiﬁ  ed 
from 1996 through 2002 (unpub. data). However, in 2003 
we identiﬁ  ed a patient in whom massive pulmonary hemor-
rhage and acute respiratory distress syndrome developed; 
subsequently, the number of cases with similar manifesta-
tions unexpectedly increased. We report the investigation 
of the emergence of SPHS in a setting where it was not 
previously observed.
The Study
The Oswaldo Cruz Foundation and State Secretary 
of Health of Bahia have conducted active surveillance 
for leptospirosis since March 1996 in the metropolitan 
region of Salvador. According to health secretary proto-
cols, suspected cases are referred to the state infectious 
disease hospital. The study team consecutively identiﬁ  ed 
case-patients who were admitted to this hospital and met 
the clinical deﬁ  nition for severe leptospirosis (11). Study 
participants were enrolled according to informed consent 
protocols approved by the Oswaldo Cruz Foundation and 
Weill Medical College of Cornell University. After the 
ﬁ  rst case was identiﬁ  ed on May 1, 2003, the study team 
prospectively identiﬁ  ed SPHS from October 2003 through 
December 2005 by evaluating patients 5 days a week for 
ﬁ  ndings of massive pulmonary hemorrhage (hemoptysis 
>300 mL or aspiration of fresh blood after endotracheal 
intubation, which did not clear with suctioning) and respi-
ratory insufﬁ  ciency (respiratory rate >30 per min or use 
of supplemental oxygen therapy). Medical records of pa-
tients hospitalized between January 2000 and September 
2003 were reviewed to identify cases that may not have 
been previously recognized.
A data-entry form was used to extract information 
from medical charts. Patients or family members were in-
terviewed to obtain information on demographics and risk 
exposures in the household and workplace. Blood samples 
were collected during hospital admission, on day 4 or 5 of 
hospitalization, and 2 weeks after the initial sample was 
obtained. Laboratory-conﬁ  rmed diagnosis of leptospirosis 
was deﬁ  ned as a 4-fold rise in titer between paired samples 
or a single titer of >800 in the microscopic agglutination 
test (MAT) (11) or a positive result on the immunoglobulin 
M (IgM) ELISA (Bio-Manguinhos, Rio de Janeiro, Bra-
zil) (13). The MAT panel included the 19 reference strains 
recommended by the World Health Organization (Royal 
Tropical Institute, the Netherlands) and a clinical isolate, 
Leptospira interrogans serovar Copenhageni strain Fiocruz 
L1–130 (11). 
Surveillance identiﬁ  ed 47 (10%) SPHS cases among 
474 patients who met the clinical deﬁ  nition for severe lepto-
spirosis from 2003 through 2005. Review of medical records 
did not identify an SPHS case before 2003. Of 47 SPHS 
cases, 37 (79%) had a conﬁ  rmed diagnosis of leptospiro-
sis. Single and paired samples were not obtained for testing 
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respectively, all of whom died during hospitalization.
Among the 47 SPHS case-patients, 7 (15%) and 20 
(42%) had pulmonary hemorrhage and respiratory insuf-
ﬁ  ciency, respectively, at the time of hospitalization (Table 
1). Pulmonary hemorrhage was identiﬁ  ed in 19 (40%) pa-
tients only after endotracheal intubation (Table 2). Except 
for respiratory insufﬁ   ciency, hemoptysis, and oliguria, 
SPHS case-patients had similar clinical manifestations to 
those of non-SPHS patients at the time of initial evaluation 
(Table 1). However, 7 (15%) and 16 (34%) of the 47 SPHS 
patients did not have signs of jaundice and acute renal in-
sufﬁ  ciency, respectively. Respiratory failure developed in 
all SPHS patients. Acute lung injury was documented in 25 
(76%) of the 33 patients for whom arterial blood gas mea-
surements were obtained (Table 2). Although patients re-
ceived supportive care with mechanical ventilation (94%), 
dialysis (53%), and packed erythrocyte transfusion (60%), 
case-fatality rate for SPHS was 74% and signiﬁ  cantly high-
er than that (12%) for non-SPHS leptospirosis (Table 1). 
By 2005, SPHS was the cause of 55% of the deaths among 
leptospirosis patients (Figure).
The annual incidence of SPHS was 0.43 cases per 
100,000 population, based on the 32 patients who resided 
within Salvador. The overall incidence of severe leptospi-
rosis was 4.65 cases per 100,000 population (341 cases). 
SPHS cases occurred during the same winter period of sea-
sonal rainfall during which non-SPHS leptospirosis cases 
were identiﬁ  ed. All SPHS case-patients were residents of 
slum settlements from which non-SPHS case-patients were 
identiﬁ  ed before and after the appearance of SPHS. Most 
SPHS case-patients were adults (mean age 37.6 ± 19.4 
years) and male (70%) (Table 1). However, women had 
higher risk (30% vs. 17%, SPHS vs. non-SPHS leptospiro-
sis; odds ratio 2.87, 95% conﬁ  dence interval 1.36–5.98) of 
acquiring SPHS. A case-control investigation did not iden-
tify signiﬁ  cant risk exposures for acquiring SPHS among 
leptospirosis cases. Serologic testing found that the high-
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Table 1. Characteristics of leptospirosis patients identified during active surveillance in metropolitan Salvador, Brazil, from 2003 
through 2005, according to presence of SPHS 
With SPHS  Without SPHS 
Characteristics 
No. 
responses 
No. (%)  
or mean ± SD 
No. 
responses 
No. (%)  
or mean ± SD  p value* 
Age, y  44  37.6 ± 19.4    427  34.9 ± 14.5  0.57 
Female sex  47  14 (30)    427  55 (13)  0.002 
Clinical  manifestations           
  Days of symptoms before hospitalization  43  6.3 ± 3.6    419  6.1 ± 2.8  0.70 
  Respiratory insufficiency†  47  20 (42)    427  73 (17)  0.001 
  Hemoptysis  47  7 (15)    427  27 (6)  0.03 
  Jaundice  47  40 (85)    427  363 (85)  0.99 
  Total serum bilirubin, mg/dL  22  17.8 ± 13.4    140  13.9 ± 10.3  0.22 
  Oliguria  47  22 (47)    427  106 (25)  0.001 
  Blood urea nitrogen, mg/dL  33  121 ± 78    254  128 ± 79  0.60 
  Serum creatinine, mg/dL  33  3.9 ± 2.3    254  3.8 ± 2.7  0.64 
  Hypotension‡  42  12 (28)    387  85 (22)  0.33 
  Leukocyte count, 10
3 cells/mm
3 45  15.3 ± 8.0    422  14.4 ± 6.5  0.71 
  Hematocrit, %  23  31.8 ± 7.1    135  33.6 ± 6.1  0.11 
  Thrombocytopenia§  21  6 (29)    120  32 (27)  0.86 
Therapeutic  interventions           
  Dialysis  47  25 (53)    425  89 (21)  0.001 
  Packed erythrocyte transfusion  47  28 (60)    424  42 (10)  0.001 
   Intensive care unit admission  47  44 (94)    424  112 (26)  0.001 
Hospital  outcome           
  Death  47  35 (74)    427  49 (12)  0.001 
  Days of hospitalization for patients who died  35  3.2 ± 2.5    49  4.8 ± 5.9  0.91 
  Days of hospitalization for survivors  12  20.8 ± 15.0    378  9.1 ± 8.4  0.02 
Confirmed case¶  47  37 (79)    427  351 (82)  0.56 
  Serovar Copenhageni as the presumptive  
 infecting  agent# 
23  22 (96)    316  285 (90)  0.71 
*The Ȥ
2 and Student t tests were used to evaluate for significant differences (p value <0.05) for proportions and continuous data, respectively. SPHS, 
severe pulmonary hemorrhagic syndrome; SD, standard deviation. 
†Respiratory rate >30 per min or use of supplemental oxygen therapy. 
‡Systolic arterial blood pressure <90 mm Hg or use of vasoactive drugs. 
§Platelet count <50,000 cells/mm
3. 
¶The microscopic agglutination test (MAT) and immunoglobulin M ELISA were used for laboratory confirmation. 
#Proportions are shown for patients who had an MAT-confirmed diagnosis of leptospirosis and highest agglutination titers against Leptospirosis 
interrogans serovar Copenhageni. Leptospirosis-associated SPHS
est agglutination titers were directed against L. interrogans 
serovar Copenhageni in 22 (96%) of 23 and 285 (90%) of 
316 SPHS and non-SPHS cases, respectively, which were 
conﬁ  rmed by MAT (Table 1). Culture isolation procedures 
were not implemented from 2001 through 2005, but an iso-
late was obtained from an SPHS patient in 2006. Serotyp-
ing procedures (11) identiﬁ  ed it as L. interrogans serovar 
Copenhageni.
Conclusions
There has been growing recognition of the importance 
of leptospirosis as the cause of SPHS (1–3). Yet except for 
a few outbreak situations (4–6), it remains unclear whether 
increased reporting represents enhanced detection of an un-
der-recognized manifestation (3) or de novo emergence of 
this disease form. This investigation identiﬁ  ed the appear-
ance of SPHS in a region in which urban leptospirosis is 
endemic and active surveillance was in place. Prior under-
recognition of this syndrome was unlikely because clini-
cians were aware of SPHS’s occurrence in other Brazilian 
cities (7,8,12). Laboratory conﬁ   rmation of leptospirosis 
was obtained for 79% of the cases, indicating that SPHS 
was due to this disease rather than to other causes of hem-
orrhagic fever. Three years after the ﬁ  rst case was identi-
ﬁ  ed, SPHS accounted for 19% of hospitalizations and 55% 
of the deaths from leptospirosis.
Our ﬁ  ndings underscore the difﬁ  culties in identifying 
SPHS, even in the setting of heightened surveillance. The 
fatality rate was 74% among SPHS patients despite aggres-
sive supportive care. Clinical parameters that could differ-
entiate patients at risk of acquiring SPHS were not found 
during initial evaluation, thereby hampering attempts to 
implement timely triage procedures. Finally, pulmonary 
hemorrhage was only identiﬁ  ed in 40% of the patients at 
the time of endotracheal intubation. Recognition of SPHS 
will therefore need to rely on a high index of suspicion in 
patients who have acute respiratory insufﬁ  ciency.
That we did not identify environmental risk exposures 
for acquiring SPHS suggests a role for pathogen or host-
speciﬁ  c factors. In Thailand, the recent sustained outbreak 
of leptospirosis was due to the widespread introduction of 
a Leptospira clone (14). Our ﬁ  ndings suggest that the agent 
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Table 2. Pulmonary manifestations of patients with leptospirosis-associated severe pulmonary hemorrhagic syndrome (n = 47) 
Characteristics* No. responses No. (%) or mean ± SD 
Onset of massive hemoptysis 
  During hospital admission  47 7 (15) 
  After hospitalization and before endotracheal intubation  47 21 (45) 
  During or after endotracheal intubation  47 19 (40) 
Chest radiographic examination 
  Bilateral alveolar infiltrates  24 21 (88) 
  Bilateral interstitial infiltrates  24 3 (12) 
PaO2/FiO2, mm Hg  33 200 ± 155 
Acute lung injury†  33 25 (76)
Acute respiratory distress syndrome‡  33 21 (64) 
*Findings at initial evaluation. SD, standard deviation. 
†Defined as a ratio between arterial partial pressure of O2 and inspired O2fraction (PaO2/FiO2)< 300 mm Hg and the presence of bilateral alveolar or 
interstitial infiltrates on chest radiograph or bilateral crepitus on physical examination, without clinical evidence of increased left atrial pressure. 
‡Defined as PaO2/FiO2 <200 mm Hg in addition to criteria for acute lung injury. 
Figure. Active hospital-based surveillance for leptospirosis in 
Salvador, Brazil, 2000–2005, including total number of suspected 
leptospirosis cases (A) and deaths (B) among case-patients. Case-
patients with and without severe pulmonary hemorrhagic syndrome 
are shown by black and gray bars, respectively.for SPHS in Salvador was L. interrogans serovar Copen-
hageni, which was also the cause of non-SPHS leptospi-
rosis in this setting (11,15). Further isolation studies and 
genotyping analyses are needed to determine whether the 
appearance of SPHS is due to introduction or emergence 
of a clone that has enhanced virulence, within this serovar. 
Gender-speciﬁ  c factors, whether risk activities or host-sus-
ceptibility determinants, may have contributed to acquiring 
SPHS because women who with leptospirosis  had twice 
the risk for this disease form. A large proportion of the 
world’s slum population resides in leptospirosis-endemic 
regions. Research is needed to elucidate the factors respon-
sible for transmission of SPHS so that effective prevention 
can be identiﬁ  ed.
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